A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant Tumors
Clinical trial NCT04353830 · COMPLETED
Trial details
- NCT number
- NCT04353830
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-22
- Primary completion
- 2022-05-11
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.